CB1151 is a 20-epi analogue of 1,25-dihydroxyvitamin D3 (VD) with potent antitumor activity; it inhibits the growth of MCF-7 breast cancer cells (IC50 = 0.82 nM); it activates the IP9-type vitamin D response element (EC50 = 1.2 nM), showing a strong correlation between antiproliferative effects and IP9-type element activation compared to DR3-type element activation (EC50 = 3.2 nM).